Panitumumab (Vectibix, Amgen, Inc.) is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). Panitumumab, formerly called ABX-EGF, was initially developed by Abgenix using the XenoMouse transgenic technology. This methodology is based on inactivating the mouse
No takes yet. Share an insight, caveat, or question.
Messersmith et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: